Technology | Contrast Media | February 02, 2017

Lantheus Medical Imaging Announces FDA Approval of Definity Label Update

Label revision removes cardiac shunt contraindication

Lantheus Medical Imaging, Definity, FDA approval, label update, echocardiography, cardiac shunt contraindication

February 2, 2017 — Lantheus Medical Imaging Inc. announced U.S. Food and Drug Administration (FDA) approval of a label update for Definity Vial for (Perflutren Lipid Microsphere) Injectable Suspension. The update removes the contraindication statement related to use in patients with a known or suspected cardiac shunt from the U.S. Prescribing Information.

Definity is indicated for use in patients with suboptimal echocardiograms to opacify the left ventricular chamber and to improve the delineation of the left ventricular endocardial border.

A cardiac shunt is a pattern of blood flow in the heart that deviates from the normal path of the circulatory system, which may present in 10 to 35 percent of patients. These patients were previously excluded from receiving a valuable echo contrast study of the left ventricle. The FDA’s decision to remove the contraindication concerning known or suspected cardiac shunts was based on Lantheus’ submission referencing several publications and data supporting the safety of echocardiography contrast products in patients with cardiac shunts. Information concerning administration in patients with a cardiac shunt appears in the Warnings section of the Definity Prescribing Information.

Neil Weissman, M.D., president of MedStar Health Research Institute (Washington, D.C.), professor of medicine at Georgetown University and past president of the American Society of Echocardiography commented, “The echocardiography medical and scientific community has long demonstrated the safety of echocardiographic contrast agents through published clinical studies which has supported the removal of the contraindication for Definity in patients with cardiac shunts. This is particularly noteworthy as Definity is the most widely used echocardiography agent in the U.S. with published data supporting its safety profile across multiple care settings and across gender and race in adults, including those age 65 and older.”

Weissman continued, “This is an important step toward broader acceptance and appropriate use of echo contrast agents, which can safely and cost effectively provide critical information to help clinicians accurately diagnose and manage patients to achieve better outcomes.”

Up to 20 percent of all resting echocardiography studies and up to 30 percent of those conducted in critical care patients can result in suboptimal echocardiograms. A suboptimal image is one in which two or more contiguous left ventricular segments in any of the three apical views cannot be visualized. The use of contrast in suboptimal echocardiograms may help with clinical evaluation of the patient.

For more information: www.lantheus.com

Related Content

ContextVision, 3-D ultrasound, SkeletalView, patent, fetal skeleton viewing, RSNA 2017
News | Advanced Visualization | March 23, 2017
ContextVision recently received a patent approval on a new skeletal visualization technology for 3-D ultrasound.
Karmanos Cancer Institute, UroNav Fusion Biopsy System, prostate cancer
News | Biopsy Systems | March 23, 2017
March 23, 2017 — Urology specialists at the Barbara Ann Karmanos Cancer Institute (Detroit) have begun using the UroN
News | Prostate Cancer | March 22, 2017
Profound Medical Corp. announced that it has successfully completed the first sale of a TULSA-PRO system in Finland to...
Carestream, Touch Prime ultrasound systems, AIUM 2017 convention, American Institute of Ultrasound in Medicine, RSNA 2017
News | Ultrasound Imaging | March 22, 2017
Carestream Health will show its Carestream Touch Prime and Touch Prime XE Ultrasound Systems at the American Institute...
Toshiba Medical, Aplio i900 cardiovascular ultrasound, FDA clearance, ACC 2017, RSNA 2017
Technology | Cardiovascular Ultrasound | March 20, 2017
March 20, 2017 — Cardiologists can now access the advanced...
Exact Imaging, Health Canada approval, ExactVu micro-ultrasound system, prostate biopsies, Sunnybrook Health Sciences Centre, Gregory Czarnota
News | Biopsy Systems | March 16, 2017
March 16, 2017 — Exact Imaging has received Health Canada approval and the corresponding medical device license (#986
PRAC, European Medicines Agency, gadolinium-based contrast agents, safety recommendations, brain MRI
News | Contrast Media | March 13, 2017
The Pharmacovigilance Risk Assessment Committee (PRAC) of the European Medicines Agency recently released new...
Technical University of Munich, Munich Compact Light Source, MuCLS, angiography, contrast agents

(a) Photograph of the sample in waterbath. (b) Empty image of full MuCLS beam. (c) Quasi-mono-energetic angiography image of a porcine heart acquired at the MuCLS, with iodine-based contrast agent injected into the left coronary artery. Visible are the left anterior descending artery (LAD) and the left circumflex artery (LCX). Image courtesy of the authors.

News | Angiography | March 10, 2017
The most prevalent method for obtaining images of clogged coronary vessels is coronary angiography. For some patients,...

Figure 1: Digital/synthetic reference object (DRO) analysis of the medical imaging market.

Feature | Imaging | March 02, 2017 | By Infinium Global Research
The emerging markets of Asia-Pacific and Latin America will drive the medical imaging market by more than 5 percent by...
contrast media
Feature | Contrast Media Injectors | March 02, 2017 | By Jeff Zagoudis
With medical imaging use on the rise, contrast media use is expected to grow as well, according to a May 2016 report...
Overlay Init